What is the new drug for type 1 diabetes? Exploring Teplizumab, Lantidra, and Emerging Therapies
•
5 min read
In November 2022, the FDA approved the first-ever disease-modifying therapy, Tzield (teplizumab), marking a monumental shift in the treatment paradigm for type 1 diabetes. For decades, insulin was the only therapeutic option, but now, a new drug for type 1 diabetes and other advanced therapies offer a proactive approach by addressing the underlying autoimmune attack on the pancreas. These breakthroughs are designed to delay onset or reduce reliance on insulin, representing the most significant treatment advancements in over a century.
